System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 39591178 DOI: 10.3390/vaccines12111275

An Optimised Live Attenuated Influenza Vaccine Ferret Efficacy Model Successfully Translates H1N1 Clinical Data.

Vaccines (Basel) 12(11)

Authors: Katarzyna E Schewe, Shaun Cooper, Jonathan Crowe, Steffan Llewellyn, Lydia Ritter, Kathryn A Ryan, Oliver Dibben

Affiliations

  • Flu-BPD, BioPharmaceutical Development, R&D, AstraZeneca, Liverpool L24 9JW, UK.
  • UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.

Abstract

Between 2013 and 2016, the A/H1N1pdm09 component of the live attenuated influenza vaccine (LAIV) produced instances of lower-than-expected vaccine effectiveness. Standard pre-clinical ferret models, using a human-like vaccine dose and focusing on antigenic match to circulating wildtype () strains, were unable to predict these fluctuations. By optimising the vaccine dose and utilising clinically relevant endpoints, we aimed to develop a ferret efficacy model able to reproduce clinical observations. Ferrets were intranasally vaccinated with 4 Log FFU/animal (1000-fold reduction compared to clinical dose) of seven historical LAIV formulations with known (19-90%) H1N1 vaccine efficacy or effectiveness (VE). Following homologous H1N1 virus challenge, protection was assessed based on primary endpoints of virus shedding in the upper respiratory tract and the development of fever. LAIV formulations with high (82-90%) H1N1 VE provided significant protection from challenge, while formulations with reduced (19-32%) VE tended not to provide significant protection. The strongest correlation observed was between reduction in shedding and VE (R = 0.75). Conversely, serum immunogenicity following vaccination was not a reliable indicator of protection (R = 0.37). This demonstrated that, by optimisation of the vaccine dose and the use of non-serological, clinically relevant protection endpoints, the ferret model could successfully translate clinical H1N1 LAIV VE data.

MeSH

Vaccines, Influenza, Human, Viruses, Influenza Vaccines, Orthomyxoviridae, Vaccine Efficacy